Last, favorable blood-brain barrier (BBB) penetration of mutant IDH inhibitors and other drugs is the foundation of synthetic lethal interaction and synergetic therapies to induce anti-tumor effects in CNS tumors, especially for gliomas. The gene discussed is IDH2; the disease is central nervous system neoplasm.